Emyria (ASX:EMD) has reported encouraging early results from its first cohort of patients in a new depression treatment program delivered through its Empax Centre network.
The company presented the findings at the International Mental Health Conference on the Gold Coast and described clinically significant reductions in depression and trauma symptoms alongside improvements in quality of life and daily functioning.
In a cohort of 10 patients with treatment-resistant depression, each patient had a baseline assessment and a follow-up at least three months after completing treatment.
Average depression symptoms fell by 6.8 points on the QIDS SR16 from 16.8 to 10.0, which the company described as a clinically significant improvement.
Emyria said the program extends its established PTSD work to a new and significant patient group and that most patients have been supported by private health insurers or other funders. Treatment is currently provided across four operational Empax clinics with a fifth planned for the third quarter of 2026, spanning Australia’s four largest states. The Therapeutic Goods Administration broadened its Authorised Prescriber pathway in May 2026, which Emyria views as evidence of growing regulatory confidence.
The company acknowledged important limitations of the analysis, including the small sample size, the fact that the reported 10 are an early subset of more than 20 patients in the program, and variable follow-up timing, which ranged from 3 to 14 months after treatment.
Chief Scientific Officer Dr Michael Winlo said, “Every patient in our first depression cohort analysed demonstrated significant improvements across depression and trauma symptoms, quality of life and everyday functioning. This is especially encouraging given these are individuals who were previously living with treatment resistant depression a major unmet need in mental health. This kind of real-world data helps improve our care models across both our TRD and PTSD programs. We look forward to sharing more as we scale.”
